The Roche deal was a validation of Zealand’s approach to tackling obesity with novel peptide-based therapies. It showed that the…
Browsing: Lillys
Novo Nordisk and Eli Lilly have established themselves as the market leaders in the obesity drug sector with their GLP-1…
Immunocore, a mid-sized drugmaker known for its successful launch of the melanoma drug Kimmtrak, is now setting its sights on…
The Food and Drug Administration recently approved Eli Lilly’s obesity drug Zepbound, also known as tirzepatide, as the first treatment…
